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Summary: The processing of synovial fluids of patients suffering from rheumatoid arthritis led to the
characterization of a neutral metalloproteinase with polymorphonuclear leukocyte progelatinase and poly-
morphonuclear leukocyte procollagenase activating properties. The activator exhibits a relative molecular
mass of Mt27000 and is an active form of Stromelysin. Thus, it reacts specifically with antibodies raised
against human Stromelysin, splits polymorphonuclear leukocyte progelatinase in a manner characteristic of
Stromelysin, and is inhibited by EDTA as well as by a tissue inhibitor of metalloproteinases (TIMP-2).
The activator shows a high specificity for the matrix metalloproteinases, polymorphonuclear leukocyte
progelatinase and polymorphonuclear leukocyte procollagenase. It shows only weak hydrolysis of casein and
gelatin, and it does not activate fibroblast Μτ 72 000 progelatinase. Brief treatment with trypsin does not lead
to a significant change in the activator's relative molecular mass, but induces a rapid loss of its activating
activity for polymorphonuclear leukocyte progelatinase, while its proteolytic activity against the synthetic
substrate, N-(2,4)-dinitrophenyl-Pro-Gln-Gly-Ile-Ala-Gly-Gln-Z)-Arg, is increased about 3-fold. The same
tryptic treatment does not affect the activator's proteolytic activity towards casein and gelatin.
Introduction ., . „ ^ , .Matrix metalloproteinases are secreted as latent pro-
Matrix metalloproteinases play an important role in enzymes by different cell types, such as fibroblasts,
remodelling of the extracellular matrix (1, 2). Since macrophages and polymorphonuclear leukocytes, in
the structural elements of the extracellular matrix are response to certain stimuli. An important regulatory
all substrates, the activity of these enzymes must be mechanism involves activation of the latent enzymes
strictly regulated. In certain diseases, e. g. rheumatoid in the extracellular space. In vitro metalloproteinases
arthritis, these control mechanisms do not function can be activated by organomercury compounds. Most
properly, leading to destruction of the extracellular matrix metalloproteinases are also activated by tryp-
matrix. In the special case of rheumatoid arthritis, sin.
destruction of the articular cartilage finally leads to jt js assumed that the physiological activator for the
the destruction of the whole joint. matrix metalloproteinases, collagenase1) and
Stromelysin1), might be plasmin1). Activated strome-
') Stromelysm EC 3.4.24.17 tysin (formerly called proteoglycanase) has a rather
Polymorphonuclear leukocyte gelatinase EC 3.4.24.35 broad spectrum of activities; it hydrolyses not only
Fibroblast collagenase EC 3.4.24 7 ^ ,
 A ^A ^ proteoglycan, but also other components of the ex-Polymorphonuclear leukocyte collagenase EC 3.4.24.34 * „ , ' . , , . . „,
Trypsin EC 3.4.21.4 tracellular matrix, such as lamimn, fibronectm, gela-
Plasmin EC 3.4.21.7 tins and collagen types III, IV, V and IX, and it is
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also reported to be a "superactivator" for plasmin-
activated collagenase, enhancing the collagenase ac-
tivity about 10-fold (3-5). Recently, it was reported
that stromelysin is an activator for polymorphonu-
clear leukocyte progelatinase (6). Thus, stromelysin is
not only an important proteinase with regard to its
activity towards components of the extracellular ma-
trix, but seems to play a key role in regulation of the
activities of other matrix metalloproteinases.
Here we report some newly discovered properties of
stromelysin (isolated from rheumatoid synovial fluid)




Rheumatoid synovial fluid originated from patients of the
Rheuma-Klinik,' Immanuel-Krankenhaus, Berlin. Buffy coat
was kindly supplied by Deutsches Rotes Kreuz, Berlin. Ultrogel
AcA 44, blue-Trisacryl, heparin-Ultrogel and phorbol myristate
acetate were purchased from Serva, Heidelberg. Gelatin-Se-
pharose was prepared in our laboratory. Sepharose 4-B was
obtained from Pharmacia, Freiburg. 4-Aminophenylmercury
acetate, plasmin (3 U/mg) and molecular mass markers for gel
electrophoresis were obtained from Sigma. Protein concentra-
tions were determined with the bicinchoninic acid reagent
(Pierce, USA) with bovine albumin as standard.
Enzyme assays
Matrix metalloproteinase activities were assayed with the syn-
thetic substrate N-(2,4)-dinitrophenyl-Pro-Gln-Gly-Ile-Ala-
Gly-Gln-Z)-Arg (dinitrophenyl-labelled peptide) (7). Activity
against protein substrates, such as gelatin and casein was as-
sayed by the fluorescamine method (8). Activator activity was
analysed by incubating the activator with polymorphonuclear
leukocyte progelatinase for 30 min at 37 °C in the presence of
the dinitrophenyl-labelled peptide. The amount of substrate
hydrolysed by the activated polymorphonuclear leukocyte ge-
latinase was taken as a measure of activator concentration.
Isolation of matrix metalloproteinases
Polymorphonuclear leukocyte progelatinase and polymorpho-
nuclear leukocyte procoilagenase were purified from buffy coat
after stimulation with phorbol-myristate acetate. The secreted
metalloproteinases were purified essentially as described (9,10).
The MT 72000 progelatinase and the MT 72000 progelatinase-
TIMP-2 complex were isolated according to 1. c. (11).
Activator purification
To 100 ml of rheumatoid synovial fluid, saturated ammonium
sulphate solution was added to 10% saturation. After 60 min
in the cold the precipitate was removed by centrifugation at
40000g for 30 min, and the clear supernatant was adjusted to
50% ammonium sulphate saturation. After 24 h at 4 °C the
precipitate was collected by centrifugation at 150000g for 20
min, washed twice with 60ml ammonium sulphate solution
(313 g/1) and centrifuged again. The sediment was dissolved in
20 mmol/1 imidazple-HCl, pH 6.1, 0.5 g/1 Brij 35, 0.5 g/1 NaN3
and dialysed against 20 mmol/1 imidazole-HCl, pH 6.1,
5 mmol/1 CaCl2, 0.5 g/1 Brij 35,0.5 g/1 NaN3 (buffer A) followed
by dialysis against buffer A. The sample was chromatographed
on carboxymethyl-trisacryl (5.5 cm χ 11 cm) equilibrated in
buffer A. After washing with buffer A, bound protein was
eluted with buffer A containing 0.5 mol/1 NaCl and stored at
—20 °C. After 300 ml of synovial fluid had been processed the
carboxymethyl-Trisacryl eluates were combined, dialysed
against 50 mmol/1 Tris-HCl, pH 7.0,200 mmol/1 NaCl, 5 mmol/1
CaCl2, 1 μηιόΐ/ΐ ZnCl2, 0.5 g/1 NaN3 (buffer B) and chromato-
graphed on gelatin-Sepharose (4 cm χ 3 cm) equilibrated in
buffer B. Unbound protein was concentrated by ultrafiltration
(Amicon, YM-10 membrane) and applied to Ultrogel AcA 44
(3 cm χ 100 cm) equilibrated in buffer B. The activator-con-
taining fractions were concentrated by ultrafiltration, dialysed
against 20 mmol/1 Tris-HCl, pH 8.0; 5 mmol/1 CaCl2, 1 μιηοΐ/l
ZnCl2, 0.5 g/1 Brij 35, 0.5 g/1 NaN3 and applied to blue-
Sepharose (2.5 cm χ 7 cm) equilibrated in the same buffer. The
activator was slightly retarded on blue-Sepharose, and activa-
tor-containing fractions were concentrated by ultrafiltration,
dialysed against buffer A and applied to heparin-Ultrogel (1.5
cm χ 8 cm) equilibrated with buffer A. The activator did not
bind to heparin-Ultrogel and was further purified by gel filtra*
tion on a calibrated AcA 44 (2crn χ 100 cm) equilibrated in
buffer B.
All following investigations of the matrix metalloproteinase
activating properties of the activator were performed with poly-
morphonuclear leukocyte progelatinase.
Demonstration of activator activity in SDS-PAGE
The procedures employed are essentially those of Hibbs et al.
(9). To determine the polymorphonuclear leukocyte progelati-
nase activating activity of the protein seen in polyacrylarnide
gel electrophpresis in the presence of sodium dodecyl sulphate
(SDS-PAGE), 1 μg activator was electrophoresed on a 12.5%
gel. After electrophoresis, the gel was washed twice for 15 min
in buffer B, pH 7.6, containing 25 g/1 Triton X-100. After
rinsing the gels briefly (5 min) in the above buffer without
Triton X-100, the gel was sliced into 1 mm sections, and each
slice was extracted with 200 ul buffer B for 24 h at 4 °C. 90 μΐ
of each extract were mixed with 10 μΐ (2 μg) polymorphonuclear
leukocyte progelatinase and 100 μί dinitrophenyl-labelled pep-
tide and incubated at 37 °C. After 24 h the amount of hydro-
lysed substrate was determined.
To examine the gelatinase activity of the protein seen on SDS-
PAGE, 60 ng activator were electrophoresed on a 10% SDS-
PAGE, containing 2 g/1 gelatin at 4 °C. The gel was washed as
described above and the zymogram was developed in 50 mmol/1
Tris-HCl, 5 mmol/1 CaCl2, 1 μηιοΐ/ΐ ZnCl2, 10 g/l Triton X-100,
0.2 g/l NaN3, pH 7.6 for 24 h at 37 °C. The gels were stained
with Coomassie brilliant blue.
pH-Optimum
Five μΐ (1 μg) polymorphonuclear leukocyte progelatinase were
incubated with 5 μΐ (15 ng) activator and 40 μΐ buffer B adjusted
to pH 6.0, 6.5, 7.0, 7.5, 8.0, 8.5 and 9.0. After l h at 37 °C,
50 μΐ of a solution containing 200 mmol/1 Tris-HCl, pH 7.0;
200 mmol/1 NaCl, 5 mmol/1 CaCl?, 0.5 g/1 NaN3 and 100 μΐ
dinitrophenyHabelled peptide were added. After an incubation
of 30 min at 37 °C the reaction was terminated and the amount
of hydrolysed dinitrophenyl-labelled peptide was determined.
Sensitivity to trypsin
3
 Activator (6 μg) in 198 μΐ buffer B was incubated with 22 μΐ
bovine trypsin (1 g/1) at 37 °C. Periodically 3.3 μΐ were taken
and added to 5 μΐ aprotinin (1 g/1) arid 81.7 μΐ buffer B to assay
the activity against polymorphonuclear leukocyte progelatinase.
To measure the activity against the dinitrophenyl-labelled pep-
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tide, 25 μΐ of the mixture were added to 5 μΐ aprotinin and 70 μΐ
buffer B. The reaction was started with either 100 μΐ dinitro-
phenyl-labelled peptide alone for 18 h (activity against dinitro-
phenyl-labelled peptide) or with the same substrate and addi-
tionally ΙΟ μΙ (2μ§) polymorphonuclear leukocyte progelati-
nase for 30 min (activator-activity).
Sensitivity to plasmin
The same procedure as described for the trypsin1) sensitivity
was applied to the investigation on the activator sensitivity
towards plasmin (l g/l).
Results
Activator purification
The amount of activator that can be isolated from
synovial rheumatoid fluid depends largely on the kind
of treatment the patients received. Treatment with
glucosteroids leads to a very low content or even a
lack of metalloproteinases in the synovial fluid. Using
only synovial fluid of patients without glucosteroid
treatment we isolated usually 30—100 μg activator
from 100 ml synovia.
Employing the method described, an activator for
polymorphonuclear leukocyte progelatinase and poly-











Polyacrylamide gel electrophoresis in the presence of
sodium dodecyl sulphate and zymogram of purified
activator.
Lane A: 1 μg activator on 12.5% polyacrylamide gel;
electrophoresis in the presence of sodium dodecyl sul-
phate. Lane B: 60 ng activator on 10% polyacrylamide;
gel electrophoresis in the presence of sodium dodecyl
sulphate containing 2g/l gelatin. Lane M: Molecular
mass markers (MT): bovine albumin (66 000), ovalbumin(45 000), glyceraldehyde-S^phosphate dehydrogenase
(36000), carbonic anhydrase (29000), trypsinogen
(24000), trypsin inhibitor (20100) and a-lactalbumin
(14200).
lecular mass of Mr 27 000 was purified from human
rheumatoid synovia. No activator could be detected
in synovial fluid itself. The activator is detectable
usually after Ultrogel AcA 44 chromatography, some-
times earlier, after gelatin-Sepharose chromatogra-
phy. Up to this purification step, identification of the
activator is based on its ability to hydrolyse the di-
nitrophenyl-labelled peptide.
The relative molecular mass of the activator was de-
termined in different ways: on a calibrated Ultrogel
AcA 44 column the activator was eluted in the range
Mr 26000-28000, in 12.5% polyacrylamide gel elec-
trophoresis in the presence of sodium dodecyl sul-
phate a main band at MT 27000 with one or two
minor bands with lower relative molecular masses
could be visualized and a gelatin-zymogram showed
proteolytic activity at the same position (fig. 1). When
larger quantities of activator were applied, an addi-
tional band at MT 25 000 was observed on the zymo-
gram. Assay of activator in eluates of sliced 12.5%
SDS-polyacrylamide gels showed activator activity
associated with the region corresponding to Mr
26000-28000.
Activity towards polymorphonuclear leuko-
cyte procollagenase and fibroblast MT 72 000
progelatinase
The activator quickly activated polymorphonuclear
leukocyte procollagenase, as already described (IS-
IS). Fibroblast MT 72000 progelatinase was not acti-
vated.
pH-Optimum
The activator shows a pH-optimum between pH 7.0
and 8.0 (data not shown).
Inhibition of the activator
The activator was inhibited by EDTA and the activity
could not be restored by dialysing against buffer B.
It was also inhibited by a slight excess of the M\
72000 progelatinase-TIMP-2 complex (fig. 2), which
acts in the same manner as TIMP-2 (11).
Trypsin-sensitivity
The activator displayed a pronounced sensitivity to
trypsin; after 30 min incubation at 37 °C more than
80% of the activator-activity was lost. In contrast,
under identical conditions, a 30 min incubation re-
sulted in a threefold enhancement of the hydrolysis
of the dinitrophenyHabelled peptide (fig. 3). Treat-
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 10
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Fig. 2. 8% Polyacrylamide gel electrophoresis in the presence
of sodium dodecyl sulphate. Inhibition of activator by
EDTA and by fibroblast Mr 72 000 progelatinase-TIMP-
2-complex.
2μ§ polymorphonuclear leukocyte progelatinase in
10 μΐ buffer Β were incubated for 45 min at 37 °C with
150 ng activator in 5 μΐ buffer B preincubated for 5 min
at 37 °C with (Lane A) 800 ng MT 72000 progelatinase-
TIMP-2 complex in 20 μΐ buffer B, (Lane B) 20 μΐ buffer
B, and (Lane C) 20 μΐ of 100 mmol/1 Tris/HCl, 50
mmol/1 EDTA, 200 mmol/1 NaCl 0.5 g/l NaN3, pH 7.0.
(Lane M). Molecular mass markers (MT): myosin
(205000), -galactosidase (116000), phosphorylase b









Fig. 3. Trypsin-sensitivity of the activator activity.
6 μg activator in 200 μΐ buffer B were incubated with
22 |ig trypsin in 22 μΐ 1 mmol/1 HC1 at 37 °C. At the
indicated times aliquots were withdrawn and activator
activity towards polymorphonuclear leukocyte proge-
latinase (open circles) and dinitrophenyl-labelled pep-
tide (solid circles) was determined.
merit with trypsin for 25 min at 37 °C did not alter
the proteolytic activity of the activator against casein
and gelatin (fig. 4). The action of trypsin reduced the
molecular mass of the activator by Mr 1000-2000,
as shown by Western-blot analysis (fig. 5). Prolonged




Fig. 4. Hydrolysis of casein (a) and gelatin (b) by the activator,
trypsin-treated activator and by trypsin.
100 μg gelatin or casein, respectively, were incubated in
a total volume of 200 μΐ buffer B with 1.2 μg activator
(open circles), 1.2 μg activator preincubated with trypsin
at 37 °C (solid triangles) or with 1.3 μg trypshi (solid
circles). At the indicated times newly generated amino
groups were determined with the fluorescamine method.
The tryptic treatment of the activator was stopped with
6 μg aprotinin after 25 min.
Plasmin-sensitivity
Under the conditions employed plasmin had no effect
on the activator (data not shown). Even an incubation
of 15 h at 37 °C did not change the activator's activity
towards polymorphonuclear leukocyte gelatinase or
the dinitrophenyl-labelled peptide.
Activation of polymorphonuclear leukocyte
gelatinase
The treatment of polymorphonuclear leukocyte pro-
gelatinase with the activator led via an Mr 86000
intermediate to an active gelatinase with a molecular
mass of Mr 82000, (fig. 6) exactly as described for
the action of Stromelysin on polymorphonuclear leu-
kocyte progelatinase (6).
Substrate specificity
The specific activity of the activator against the di-
nitrophenyl-labelled peptide was 40 mU/mg, which is
about 4% of polymorphonuclear leukocyte gelatinase
activity against that substrate (11). It can be deduced
from figure 4 that the activator's activity against
casein is about 3 times higher than against gelatin.
Compared with trypsin, however, the activator's acti-
vity towards these substrates is rather low, i.e. less
than 10% of the trypsin activity towards gelatin and
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 10
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Fig. 5. Immunoblotting of activator and of trypsin treated ac-
tivator.
600 ng activator in 20 μΐ buffer Β (Lane A) and 600 ng
activator in 20 μΐ buffer Β incubated with 2 μg trypsin
in 2 μΐ 1 mmol/1 HC1 at 37 °C for 30 min (Lane B) were
run on a 12.5% polyacrylamide gel in the presence of
sodium dodecyl sulphate, blotted on a Millipore Im-
mobilon membrane and blocked overnight with bovine
serum albumin. The blots were incubated with an an-
tiserum raised in sheep against human Stromelysin, fol-
lowed by peroxidase-labelled anti-sheep-IgG. The re-
active bands were visualized with 4-chloro-l-naphthol.
The tryptic treatment was stopped with 2 μg aprotinin
in 2 μΐ distilled water. The position of the apparent
molecular mass for prestained protein is indicated: β-
galactosidase (116 000), fructose-6-phosphate kinase
(96400), pyruvate kinase (80400), ovalbumin (55700),
lactic dehydrogenase (43 700) and triosephosphate iso-
merase (38 800).
about 20% of that towards casein. Trypsin and acti-
vator are compared with respect to their polymor-
phonuclear leukocyte progelatinase activating pro-
perties in table 1, where it can be seen that the rela-
tionship is reversed, i.e. the activator is nearly 30
times more efficient than trypsin in the activation of
polymorphonuclear leukocyte progelatinase.
Tab. 1. Activation of polymorphonuclear leukocyte progelati-
nase by activator and trypsin
2 μg polymorphonuclear leukocyte progelatinase in 100
μΐ buffer B and varying amounts of activator displaying
a molecular mass of Mr 27 000 or bovine trypsin dis-
playing molecular mass of Mr 24 000, respectively, were
mixed with 50 μg dinitropheiayl-labeiled peptide in 100


































Fig. 6. Activation of polymorphonuclear leukocyte progelati-
nase with activator.
l μg polymorphonuclear leukocyte progelatinase in 5 μΐ
buffer B was incubated with 30 ng activator in 1 μΐ
buffer B for 60 (Lane A), 45 (Lane B), 30 (Lane C), 20
(Lane D), 10 (Lane E), 5 (Lane F) and 0 (Lane G) min,
respectively, and analysed on 8% polyacrylamide gel
electrophoresis in the presence of sodium dodecyl sul-
phate. Lane M: molecular mass markers (Mr): myosin
(205 000), -galactosidase (116 000), phosphorylase
97400), bovine albumin (66000) and ovalbumin
(45000).
Discussion
From the synovial fluid of patients suffering from
rheumatoid arthritis, we isolated an activator for
polymorphonuclear leukocyte procollagenase and
polymorphonuclear leukocyte progelatinase, with a
relative molecular mass of MT 27000. Furthermore,
we demonstrated that the activator is an active form
of the matrix metall proteinase Stromelysin; the ac-
tivator is inhibited by EDTA and the MT 72000 ge-
latinase-TIMP-2 complex, which acts as an inhibitor
for matrix metalloproteinases the same way as TIMP
(11), thereby establishing that the activator is a mem-
ber of the family of matrix metalloproteinases. The
activator reacts with antibodies raised against human
Stromelysin, its pH-optimum lies in the neutral range,
and it splits the polymorphonuclear leukocyte gela-
tinase in a manner characteristic of Stromelysin.
The activator was not only found in synovia of pa-
tients suffering from rheumatoid arthritis but also in
the synovia of patients with osteoarthritis or systemic
lupus erythematosus during an inflammatory attack.
The activator could not be detected in synovia from
non-inflammatory joints, e. g. distorsion of the knee.
Synovia subsequently found to contain a high con-
centration of activator also displayed a general en-
hancement of matrix metall proteinase activity. Ac-
tivator activity was not detectable in synovial fluids
but became apparent after the Chromatographie step
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 10
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on Ultrogel AcA 44, sometimes earlier, after gelatin-
Sepharose. Latent prostromelyin is therefore activated
during the purification procedure. Whether this is due
to the action of other proteinases or to an autocata-
lytic process is still unclear.
We believe that an activator for polymorphonuclear
leukocyte collagenase and polymorphonuclear leu-
kocyte gelatinase that was isolated from synovial fluid
(12-14) and from the culture media of synoviocytes
(15) many years ago is also stromelysin. However,
this activator had a reported relative molecular mass
of MT 35 000 and it lacked proteolytic activity against
casein and gelatin. We could not detect activator
activity in the relative molecular mass range of Mr
35 000, either on a calibrated Ultrogel AcA 44, or by
eluting protein from sliced SDS-polyacrylamide elec-
trophoresis gels.
Polymorphonuclear leukocyte progelatinase, poly-
morphonuclear leukocyte procollagenase, fibroblast
Mr 72000 progelatinase, casein, gelatin and dinitro-
phenyl-labelled peptide were examined as substrates
for the proteolytic activity of the activator. With the
exception of the fibroblast Mr 72000 progelatinase,
the activator hydrolysed all these substrates, but
showed a rather high degree of specificity for poly-
morphonuclear leukocyte progelatinase and polymor-
phonuclear leukocyte procollagenase. The activator
was much less active than trypsin in the proteolysis
of casein and gelatin. However, although trypsin is a
potent activator for polymorphonuclear leukocyte
progelatinase (16), the stromelysin activator is about
30 times more efficient. The activator displays a simi-
lar efficiency in the activation of polymorphonuclear
leukocyte collagenase, while the fibroblast MT 72 000
progelatinase is not a substrate for the activator. The
high specificity for the matrix metalloproteinases dis-
played by neutrophilic granulocytes may indicate a
physiological role of this activator in the activation
of these proteinases. This specificity may also explain
why the MT 35 000 activator described earlier was not
found to hydrolyse gelatin and casein; activator con-
centrations too low to significantly hydrolyse gelatin
and casein are still sufficient to rapidly activate the
polymorphonuclear leukocyte progelatinase.
Hydrolysis of the dinitrophenyl-labelled peptide by
the activator was slow compared with the rate of
hydrolysis by polymorphonuclear leukocyte gelati-
nase. However, a short tryptic treatment, that did not
lead to a significant change in the molecular mass of
the activator (fig. 5), enhanced the activator's activity
against the dinitrophenyl-labelled peptide about
threefold, destroyed its ability to activate polymor-
phonuclear leukocyte progelatinase and did not affect
its activity against casein and gelatin. It might there-
fore be concluded that a similar physiological proteo-
lytic event may significantly increase the activator's
activity against some components of the extracellular
matrix. Plasmin, a proteinase with proteolytic proper-
ties similar to trypsin, plays an important role under
physiological conditions in the activation of procol-
lagenase (MMP-1) and prostromelysin, but it had no
effect on the activator.
It could be argued that the three different trypsin
sensitivities of the activator might be due to the pres-
ence of two different proteinases that react with tryp-
sin in different ways:
1. the activator (active stromelysin) which hydrolyses
the dinitrophenyl labelled peptide, casein/gelatin
and the polymorphonuclear leukocyte progelati-
nase, and which is inactivated by trypsin;
2. a latent metalloproteinase which, after activation
by trypsin, could be responsible for the enhanced
turnover of the dinitrophenyl labelled peptide, and
which at the same time compensates the loss of the
caseinolytic/gelatinolytic activity of the activator.
According to the relative molecular mass this me-
talloproteinase could only be matrilysin (MMP-7),
but so far this enzyme has only been found in the
uterus (17) and in developing macrophages (18).
In addition, in synovial fluid, no such small latent
metalloproteinase could be detected after chro-
matography on Ultrogel AcA 44 (not shown).
The distinct sensitivity to trypsin of the activator's
proteolytic activity towards different substrates sug-
gests that during the transformation from prostro-
melysin to active stromelysin at least one switch po-
sition is passed. At this switch position a putative
regulatory mechanism may have the option of quickly
deciding whether stromelysin should function as an
activator for matrix metalloproteinases, or conco-
mitantly, with enhanced activity, as a proteinase of
other substrates.
Recently, it was reported that treatment of prostro-
melysin withp-aminophenylmercury acetate led to the
formation of an activator for polymorphonuclear leu-
kocyte progelatinase with a relative molecular mass
of Μτ 47000 (6). This activator was not investigated
with regard to its sensitivity to trypsin and it would
be interesting to know if this Mr 47000 activator
behaves in the same way as the Μτ 27 000 activator
. described in the present report.
The activity of matrix metalloproteinases in the ex-
tracellular space is subject to regulation on at least
three different levels — expression, activation, and
interaction with specific inhibitors. The present data
Eur. J. Clin. Cheiii. Clin. Biochem. / Vol. 31,1993 / No. 10
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extend this regulatory repertoire by the observation
that stromelysin may be further processed to active
species displaying distinct and separate functions as
activators or hydrolytic enzymes of macromolecules
of the extracellular matrix.
We are now investigating whether a mechanism is
present in the synovial fluid of patients afflicted by
rheumatoid arthritis, which under physiological con-
ditions may initiate a cascade of events, producing
and processing stromelysin as described here in vitro.
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